NCT07392229RecruitingPhase 2
Zanubritnib and anti-MAG neuropathy
ZANUBRUTINIB, A SECOND GENERATION BTK INHIBITOR, IN ANTI-MAG ANTIBODY NEUROPATHY: A PHASE II ITALIAN MULTICENTER CLINICAL TRIAL (MAZINGA)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Apr 2026
Brief summary (registry, in English)
To investigate whether 12 months zanubrutinib treatment lead to an improvement of at least 1 point in at least 2 neurological scales, such as Overall Neuropathy Limitations Scale (ONLS), INCAT disability, INCAT sensory sum scores (ISS), MRC sum score, I-RODS functional score.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 24 Sept 2025
- Start date
- 24 Mar 2026
- Lead sponsor
- Azienda Ospedaliera di Padova
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07392229
- EU CT number
- 2025-523091-23-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Lab values
- ● Previous treatment with BTK inhibitors ● Aggressive non-Hodgkin lymphoma or IgM multiple myeloma ● Evidence of moderate or severe motor nerve axonal damage ● ECOG >3 ● Requiring ongoing therapy with strong or moderate cytochrome P450 3A (CYP3A) inducer. Use of strong/moderate CYP3A inducers within 14 days prior to the first dose of zanubrutinib (see Drug-interaction section). ● creatinine clearance <30mL/min
Who the study is looking for
- ● Age ≥18 years; ● diagnosis of anti-MAG antibody polyneuropathy; ● diagnosis of anti-MAG antibody polyneuropathy; ● IgM monoclonal protein underlying MGUS, Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified; ● Presence of anti MAG antibodies (titer ≥ 7.000 BTU)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Ospedale Policlinico San Martino Coordinator of this site? Confirm its status | Genoa | Italy | Recruiting |
| ASST Grande Ospedale Metropolitano Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
| Azienda Ospedaliera di Padova Coordinator of this site? Confirm its status | Padova | Italy | Recruiting |
| Fondazione IRCCS Policlinico San Matteo Coordinator of this site? Confirm its status | Pavia | Italy | Recruiting |
| Azienda Ospedaliera Policlinico Universitario Tor Vergata Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
| Humanitas Mirasole S.p.A. Coordinator of this site? Confirm its status | Rozzano | Italy | Recruiting |
| Azienda Sanitaria Universitaria Giuliano Isontina Coordinator of this site? Confirm its status | Trieste | Italy | Recruiting |
| Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino Coordinator of this site? Confirm its status | Turin | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.